FAQ: NanoViricides' NV-387 Antiviral Drug Shows Promise Against Measles
Summary
NanoViricides' clinical lead drug candidate NV-387 demonstrated strong antiviral activity against Measles virus in studies, extending survival by 130% in infected mice while protecting lung tissue from damage. This is significant as there are currently no approved drugs for Measles treatment, positioning NV-387 as a potential first-in-class therapeutic.
What is NV-387 and what did the study demonstrate?
NV-387 is NanoViricides’ clinical lead drug candidate that demonstrated potent antiviral effects against Measles virus in both cell culture studies and a humanized animal model, extending survival in infected mice by 130% while significantly protecting lung tissue from viral and immune-related damage.
Why is this development significant for Measles treatment?
This is significant because there are currently no approved drugs specifically for Measles treatment, making NV-387 a potential first-in-class therapeutic candidate that could address this unmet medical need.
How does NV-387 work against Measles infection?
NV-387 has dual action - it provides direct viral suppression and mitigates systemic and lung inflammation, resulting in reduced lung plaques, slower disease progression, and improved overall health outcomes in treated animals.
What specific results were observed in the animal studies?
In infected mice, NV-387 treatment extended survival from 7.4 to 17 days (130% increase) while significantly protecting lung tissue from both viral and immune-related damage.
What is NanoViricides and what is their business model?
NanoViricides is a publicly traded clinical stage company that creates special purpose nanomaterials for antiviral therapy, with a business model based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses.
What other viral diseases is NV-387 being developed to treat?
NV-387 is planned as a broad-spectrum antiviral drug for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.
What is the current development status of NV-387?
The Company is currently focused on advancing NV-387 into Phase II human clinical trials, though they cannot project an exact date for filing an IND due to dependence on external collaborators and consultants.
What other drug candidates does NanoViricides have in development?
Their other advanced drug candidate is NV-HHV-1 for the treatment of Shingles, and they are developing drugs against numerous other viral diseases including oral and genital Herpes, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.
Where can I find more detailed information about this announcement?
The full press release is available at https://ibn.fm/MhcmX and more company information can be found at https://www.nanoviricides.com/.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 262292